Project Grant HT94252310417
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded Health Research, Inc. a $1,545,300 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING MYCAF-DRIVEN CASTRATION-RESISTANT PROSTATE TUMOR GROWTH." The award, which has a performance period of May 1, 2024 to April 30, 2027, will enable Health Research, Inc.'s Roswell Park Division to perform biomedical research and provide scientific services to advance...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...
The federal Project Grant award, valued at $1,944,610.00 and effective from April 1, 2025 to March 31, 2028, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The primary awardee, Sloan-Kettering Institute for Cancer Research, will conduct research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. This work will involve collaboration with The University of Texas MD Anderson Cancer...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $171,700 to Health Research, Inc. to conduct research on the "Mechanism of Anti-SEMA4D Therapy Reversal of Immunosuppression in the Prostate Tumor Microenvironment." The 2-year research project aims to investigate novel cancer immunotherapy approaches to treat prostate cancer. As a non-profit organization, Health Research, Inc. collaborates extensively...
The Department of the Army Medical Command awarded a $576,001 Project Grant to Cold Spring Harbor Laboratory to support research titled "Role of the Tumor Neuroenvironment in Prostate Cancer Metastasis." The two-year award running from August 1, 2022 to July 31, 2024 will fund research investigating the role of the tumor microenvironment in prostate cancer metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program...
The federal Project Grant award of $2,028,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award is for a project titled "IDENTIFICATION OF EPIGENETICALLY DRIVEN VULNERABILITIES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER" with a performance period from Apr 1, 2025 to Mar 31, 2028. The grant was awarded to the Icahn School of Medicine at Mount Sinai, a leading academic medical center and...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...